Literature DB >> 26634858

Adherence and Persistence Patterns in Medication Use Among Men With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

Emily Shortridge1, Craig Donatucci1, Prina Donga2, Michael Marcus2, Rolin L Wade2.   

Abstract

Medication adherence and persistence patterns among patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) were analyzed. Electronic medical records of patients from the Reliant Medical Group were examined to evaluate adherence and persistence patterns. A total of 1,807 patients with LUTS/BPH were included in the study, and the number of patients at least 50 years of age was 1,748/1,807 (97%). Overall, 15.77% of patients were prescribed index prescription once, and no patients on combination alpha-blocker and 5-alpha reductase inhibitor therapies were prescribed their index prescriptions once. For all patients with LUTS/BPH, the mean number of prescriptions filled was 6.26, and the percentage of men persisting on index therapy for ≥4 years was 48%. Patients with LUTS/BPH showed a high proportion of both adherent and persistent treatment patterns, especially among patients taking combination therapy. The long follow-up time in our study provides evidence that patients are experiencing sufficient symptom relief to tolerate the challenges of remaining adherent and persistent.

Entities:  

Keywords:  benign prostatic hypertrophy; erectile dysfunction; outcomes research

Year:  2016        PMID: 26634858      PMCID: PMC5675169          DOI: 10.1177/1557988315616676

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  18 in total

1.  The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis.

Authors:  B Eryildirim; A Aktas; U Kuyumcuoglu; G Faydaci; F Tarhan; A Ozgül
Journal:  Int J Impot Res       Date:  2010-10-28       Impact factor: 2.896

2.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

3.  Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

Authors:  B Lukacs; A Leplège; P Thibault; A Jardin
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

4.  Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.

Authors:  Adolfo Casabé; Claus G Roehrborn; Luigi F Da Pozzo; Sebastian Zepeda; R Jonathan Henderson; Sebastian Sorsaburu; Carsten Henneges; David G Wong; Lars Viktrup
Journal:  J Urol       Date:  2013-10-02       Impact factor: 7.450

5.  Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia.

Authors:  Michael B Nichol; Tara K Knight; Joanne Wu; Richard Barron; David F Penson
Journal:  J Urol       Date:  2009-03-17       Impact factor: 7.450

6.  Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project.

Authors:  K M C Verhamme; J P Dieleman; G S Bleumink; J L H R Bosch; B H Ch Stricker; M C J M Sturkenboom
Journal:  Eur Urol       Date:  2003-11       Impact factor: 20.096

7.  Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Authors:  Christopher P Filson; John T Wei; John M Hollingsworth
Journal:  Urology       Date:  2013-10-23       Impact factor: 2.649

8.  Treatment patterns in alpha-blocker therapy for benign prostatic hyperplasia.

Authors:  Michael J Schoenfeld; Emily F Shortridge; Steven C Gelwicks; Zhanglin Cui; David G Wong
Journal:  Am J Mens Health       Date:  2013-11-20

9.  The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

Authors:  C G Roehrborn; J E Oesterling; S Auerbach; S A Kaplan; L K Lloyd; D E Milam; R J Padley
Journal:  Urology       Date:  1996-02       Impact factor: 2.649

Review 10.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

View more
  3 in total

1.  Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mera Ababneh; Duaa Shamieh; Saddam Al Demour; Abeer Rababa'h
Journal:  Int J Clin Pharm       Date:  2019-09-06

2.  A randomized placebo-controlled study: Phellodendron Bawei tablets combined with standard management can improve storage symptoms, sleep quality, and medication compliance in patients with benign prostatic hyperplasia compared to placebo with standard management.

Authors:  Yu-Chen Gong; Xiang Chen; Qing-Tian Song; Yu Gan; Bo Zhang; Bing-Sheng Li; Zhi Chen; Yao He
Journal:  Transl Androl Urol       Date:  2021-08

Review 3.  Pharmacology of the lower urinary tract: update on LUTS treatment.

Authors:  Pedro Abreu-Mendes; João Silva; Francisco Cruz
Journal:  Ther Adv Urol       Date:  2020-05-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.